Women's Pro Sports & Cannabis: WNBA, NWSL, Title IX Equity
Women's pro-sports cannabis policy: WNBA still tests with limited fines (2020 CBA, renegotiation 2025-26), NWSL doesn't test, the asymmetry with the NBA, and Title IX equity in NCAA cannabis enforcement.
WNBA: Tests Under 2020 CBA, Renegotiating for 2026+ Tested, fines only
The WNBA continues to test for cannabis under its CBA (ratified 2020, currently being renegotiated for a 2026+ term as of late 2025). Limited use is allowed before tiered fines escalate. The framework sits between the NBA's full 2023 removal and the WADA-aligned MLS posture — closer to the NFL's post-2024 fine-only approach than to either pole.
The cannabis-policy discussion in the 2025-26 WNBA CBA negotiations is not separable from the league's broader wage-parity context. WNBA players supplement domestic salaries by playing overseas during the WNBA off-season — exactly the cross-border posture that the Griner case reframed.
The Brittney Griner Case Reframed Every WNBA-Overseas Conversation
On February 17, 2022, Phoenix Mercury center Brittney Griner was detained at Sheremetyevo airport (Moscow) on possession of two cannabis-vape cartridges — for which she held a medical prescription in Arizona. On August 4, 2022, a Russian court sentenced her to nine years in a penal colony. On December 8, 2022, she was released in a prisoner swap for arms dealer Viktor Bout. Read the full Griner timeline.
Three concentric implications:
- Travel risk: Country-by-country legal differences make hemp-CBD travel hazardous regardless of home-jurisdiction legality. Griner is the extreme case, not the only case.
- Wage parity: The economic pressure that drives WNBA players overseas is itself a cannabis-policy variable. As long as off-season foreign play remains economically necessary for many WNBA players, jurisdiction-mismatch risk follows.
- Policy asymmetry: A Phoenix Mercury player and a Phoenix Suns player can use the same product on the same day with materially different consequences — the former under WNBA testing, the latter under the NBA's 2023 removal.
NWSL: Doesn't Test, Explicitly Permits Cannabis-Brand Sponsorships Removed from list
The National Women's Soccer League does not test for cannabis under its 2022 CBA and explicitly permits cannabis-brand sponsorships — distinguishing it from MLS within U.S. soccer. (MLS follows WADA at 150 ng/mL in-competition because of its FIFA affiliation; see MLS, NWSL, WNBA Policy.) NWSL's posture aligns more closely with the post-2023 NBA framework than with FIFA-affiliated soccer's WADA alignment.
The NWSL/MLS divergence inside U.S. soccer is the cleanest illustration in U.S. team sport that women's-league cannabis posture is not institutionally more punitive than men's-league posture — it is league-by-league, CBA-by-CBA, and FIFA-affiliation-by-affiliation. The asymmetry that matters is league-internal (NBA vs. WNBA), not gender-categorical.
Recommendation: Replicate the NBA's 2023 Framework in the Next WNBA CBA
From this site's research recommendations: "For the WNBA: replicate the NBA's 2023 framework in the next CBA cycle. The asymmetry between an NBA player and a WNBA player on the same drug is indefensible."
The intellectual case is straightforward. The NBA-NBPA April 26, 2023 CBA — effective July 1, 2023, runs through 2029-30 — removed marijuana from the Prohibited Substances List, permits passive (≤50%) investment in cannabis companies, and permits active promotion of CBD-only brands (defined as ≤0.3% THC by dry weight, mirroring the federal hemp definition). A parallel WNBA framework would:
- Eliminate the same-drug asymmetry between the two leagues operating under the same parent organization.
- Reduce the entanglement between testing positivity and overseas play (since out-of-competition cannabis would no longer be a domestic-league disciplinary issue).
- Open the same NIL-style cannabis brand-deal ecosystem (athlete-founded cannabis brands) to WNBA players that NBA players have under the 2023 CBA.